Journal of Ophthalmic and Vision Research
ISSN: 2008-322X
The latest research in clinical ophthalmology and the science of vision.
Intravitreal Injections and Face Masks: Endophthalmitis Risk Before and During the COVID-19 Pandemic
Published date: Jul 23 2023
Journal Title: Journal of Ophthalmic and Vision Research
Issue title: July–September 2023, Volume 18, Issue 3
Pages: 283–288
Authors:
Abstract:
Purpose: To assess the added risk of acute endophthalmitis after intravitreal injections associated with the widespread use of face masks during the COVID-19 pandemic.
Methods: In this retrospective, single-center study, records of patients with acute endophthalmitis following intravitreal bevacizumab (IVB) injections during the pre-COVID era—that is, March 1st , 2013 to October 31st, 2019 —and the COVID-19 era—that is, March 1st, 2020 to April 1st, 2021 —were reviewed and compared.
Results: A total of 28,085 IVB injections were performed during the pre-COVID era; nine eyes of nine patients developed acute post-IVB endophthalmitis in this era, giving an overall incidence of 0.032% (3.2 in 10,000 injections). In the COVID era, 10,717 IVB injections were performed; four eyes of four patients developed acute post-IVB endophthalmitis in this era, giving an overall incidence of 0.037% (3.7 in 10,000 injections). The incidences of post-IVB endophthalmitis during these two eras were not statistically significantly different (P = 0.779).
Conclusion: Face masking protocols seem unlikely to impose any additional risk of post-IVB endophthalmitis.
Keywords: COVID-19; Endophthalmitis; Face Mask; Intravitreal Injection; Infection
References:
1. Maloney MH, Payne SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of systemic adverse events after intravitreal bevacizumab, ranibizumab, and aflibercept in routine clinical practice. Ophthalmology 2021;128:417–424.
2. Soliman MK, Gini G, Kuhn F, Iros M, Parolini B, Ozdek S, et al. International practice patterns for the management of acute postsurgical and postintravitreal injection endophthalmitis: European Vitreo-Retinal Society endophthalmitis study report 1. Ophthalmol Retina 2019;3:461–467.
3. Lyall DA, Tey A, Foot B, Roxburgh ST, Virdi M, Robertson C, et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: Incidence, features, risk factors, and outcomes. Eye 2012;26:1517–1526.
4. Fintak DR, Shah GK, Blinder KJ, Regillo CD, Pollack J, Heier JS, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008;28:1395–1399.
5. Klompas M, Morris CA, Sinclair J, Pearson M, Shenoy ES. Universal masking in hospitals in the Covid-19 era. N Engl J Med 2020;382:e63.
6. Al-Sayah MH. Chemical disinfectants of COVID-19: An overview. J Water Health 2020;18:843–848.
7. Rabenau HF, Kampf G, Cinatl J, Doerr HW. Efficacy of various disinfectants against SARS coronavirus. J Hosp Infect 2005;61:107–111.
8. Advani SD, Smith BA, Lewis SS, Anderson DJ, Sexton DJ. Universal masking in hospitals in the COVID-19 era: Is it time to consider shielding? Infect Control Hosp Epidemiol 2020;41:1066–1067.
9. Wang X, Ferro EG, Zhou G, Hashimoto D, Bhatt DL. Association between universal masking in a health care system and SARS-CoV-2 positivity among health care workers. JAMA 2020;324:703–704.
10. Wen JC, McCannel CA, Mochon AB, Garner OB. Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol 2011;129:1551– 1554.
11. Patel SN, Hsu J, Sivalingam MD, Chiang A, Kaiser RS, Mehta S, et al. The impact of physician face mask use on endophthalmitis after intravitreal anti-vascular endothelial growth factor injections. Am J Ophthalmol 2021;222:194– 201.
12. Storey P, Dollin M, Pitcher J, Reddy S, Vojtko J, Vander J, et al. The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection. Ophthalmology 2014;121:283–289.
13. Xu K, Chin EK, Bennett SR, Williams DF, Ryan EH, Dev S, et al. Endophthalmitis after intravitreal injection of vascular endothelial growth factor inhibitors: Management and visual outcomes. Ophthalmology 2018;125:1279–1286.
14. Rayess N, Rahimy E, Storey P, Shah CP, Wolfe JD, Chen E, et al. Postinjection endophthalmitis rates and characteristics following intravitreal bevacizumab, ranibizumab, and aflibercept. Am J Ophthalmol 2016;165:88–93.
15. Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999;26:259–265.
16. Patel SN, Tang PH, Storey PP, Wolfe JD, Fein J, Shah SP, et al. The influence of universal face mask use on endophthalmitis risk after intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 2021;128:1620–1626.
17. Doshi RR, Leng T, Fung AE. Reducing oral flora contamination of intravitreal injections with face mask or silence. Retina 2012;32:473–476.
18. Hadayer A, Zahavi A, Livny E, Gal-Or O, Gershoni A, Mimouni K, et al. Patients wearing face masks during intravitreal injections may be at a higher risk of endophthalmitis. Retina 2020;40:1651–1656.
19. Patel SN, Mahmoudzadeh R, Salabati M, Soares RR, Hinkle J, Hsu J, et al. Bacterial dispersion associated with various patient face mask designs during simulated intravitreal injections. Am J Ophthalmol 2021;223:178–183.
20. Schultheis WG, Sharpe JE, Zhang Q, Patel SN, Kuriyan AE, Chiang A, et al. Effect of taping face masks on quantitative particle counts near the eye: Implications for intravitreal injections in the covid-19 era. Am J Ophthalmol 2021;225:166–171.
21. Al-Khersan H, Kalavar MA, Tanenbaum R, Lazzarini TA, Patel NA, Yannuzzi NA, et al. Emergent ophthalmic surgical care at a tertiary referral center during the COVID-19 pandemic. Am J Ophthalmol 2021;222:368–372.
